Table 2 Characteristics of patients with falling pembrolizumab drug level and rising anti-drug antibody level.
From: Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
Patient | Sex | Age (years) | Stage | Pembrolizumab level B/L (ng/μL) | Pembrolizumab level T1 (ng/μL) | Pembrolizumab level T2 (ng/μL) | ADA level B/L (ng/μL) | ADA level T1 (ng/μL) | ADA level T2 (ng/μL) | Progression at 6 months |
|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 66 | 4 | 0 | 469 | 375 | 0 | 2 | 5 | Partial response |
2 | M | 75 | 4 | 0 | 361 | 272 | 5 | 0 | 7 | No Progression |
3 | F | 72 | 4 | 0 | 434 | 359 | 0 | 0 | 3 | No Progression |
